Arcus Biosciences, Inc.(RCUS)— Stock Profile, AI Score & Financials

Healthcare · NYSE · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Arcus Biosciences, Inc. (RCUS) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores RCUS at 8.5/100 on a 32-signal composite quality model, placing it at rank #2,927 of 2,960 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue growth (1.9) and free cash flow (3.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 7.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Arcus Biosciences, Inc. reports quarterly revenue of $41.0M, net income of $-91.0M, free cash flow of $-119.0M. Top institutional holders of RCUS by reported 13-F value include GILEAD SCIENCES, BlackRock, STATE STREET, based on the most recent SEC filings. RCUS trades on the NYSE exchange and files with the SEC under CIK 1724521. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RCUS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Arcus Biosciences, Inc. directly from SEC EDGAR.